MIDATECH PHARMA
Media
Jul 18, 2017
Trading Update and Notice of Results

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

Jun 13, 2017
R&D manufacturing site visit for investors and analysts

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Jun 9, 2017
Midatech signs global license agreement to investigate panobinostat for treatment of brain cancers

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

May 22, 2017
Midatech announces progress update on brain cancer therapies

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products... read more >

Apr 11, 2017
Notice of Annual General Meeting 2017
Apr 4, 2017
Audited financial results for the year ended 31 December 2016

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Mar 10, 2017
Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility

~ Q-Octreotide will become Midatech’s first Sustained Release product candidate manufactured in house at its state-of-the-art... read more >

Jan 20, 2017
Trading Update

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

 

Media
Jul 18, 2017
Trading Update and Notice of Results

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

Jun 13, 2017
R&D manufacturing site visit for investors and analysts

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Jun 9, 2017
Midatech signs global license agreement to investigate panobinostat for treatment of brain cancers

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

May 22, 2017
Midatech announces progress update on brain cancer therapies

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising products... read more >

Apr 11, 2017
Notice of Annual General Meeting 2017
Apr 4, 2017
Audited financial results for the year ended 31 December 2016

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products... read more >

Mar 10, 2017
Midatech Announces Successful Initial Scale-Up of Its Sustained Release Manufacturing Facility

~ Q-Octreotide will become Midatech’s first Sustained Release product candidate manufactured in house at its state-of-the-art... read more >

Jan 20, 2017
Trading Update

Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and... read more >

© Copyright 2017 Midatech Pharma PLC